JPM23: Vaccine Developers as Dealmakers, Gilead’s Trial Tea Leaves and Building Platform Companies
Troutman Pepper Partner Chris Miller was quoted in the January 10, 2023 BioPharma Dive article, " JPM23: Vaccine Developers as Dealmakers, Gilead’s Trial Tea Leaves and Building Platform Companies."
Across the industry, biotechs are having difficulty going public. Startups are struggling to bring new investors in and to raise new rounds at higher values, said Chris Miller, a partner and leader of Troutman Pepper's emerging companies and venture capital team.